ARKG — ARK Genomic Revolution ETF
Data updated: 2026-06-23
ARKG — ARK Genomic Revolution ETF data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. United States Health Care Equity · $1.24B AUM · 0.75% expense ratio · 35.8% 1-yr return. From SEC regulatory filings.
ARKG Fund Overview
ARKG — ARK Genomic Revolution ETF is a US ETF managed by ARK ETF Trust, categorised as United States Health Care Equity. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: ARK ETF Trust
- Category: United States Health Care Equity
- Assets under management: $1.24B
- 1-year return: 35.8%
- Ticker: ARKG
- SEC CIK: 0001579982
- SEC series ID: S000042975
- Share class ID: C000133119
ARKG Holdings
Top 10 holdings of ARK Genomic Revolution ETF by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Tempus Ai, Inc. | 9.42% |
| Twist Bioscience Corp. | 8.99% |
| Crispr Therapeutics AG | 8.91% |
| 10x Genomics, Inc. | 5.77% |
| Beam Therapeutics, Inc. | 5.43% |
| Absci Corp. | 4.78% |
| Natera, Inc. | 4.07% |
| Illumina, Inc. | 4.03% |
| Intellia Therapeutics, Inc. | 3.82% |
| Personalis, Inc. | 3.58% |
ARKG Portfolio Allocation
Asset-class allocation of ARK Genomic Revolution ETF by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 99.6% |
| Cash & Equivalents | 0.1% |
ARKG Performance
Total returns for ARKG (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 3.3% |
| 1 year | 35.8% |
| 3 years (annualised) | 1.1% |
| 5 years (annualised) | -19.5% |
ARKG Risk Information
Risk metrics for ARKG, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 31.0%
ARKG Costs and Fees
ARKG costs about $75 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.75%
- Gross expense ratio: 0.75%
- Portfolio turnover: 33%
- Brokerage commissions: 5.87 bps of average net assets (SEC N-CEN)
ARKG Cashflows
Over the 12 months to 2026-04, ARK Genomic Revolution ETF had net outflows of $12.96M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | $59.51M |
| 2026-03 | −$112.72M |
| 2026-02 | $39.77M |
| 2026-01 | $52.45M |
| 2025-12 | $9.09M |
| 2025-11 | −$56.44M |
ARKG Debt Constituents
No individual debt constituents are reported in ARK Genomic Revolution ETF's latest SEC N-PORT filing.
ARKG Prospectus and SEC Filings
Official ARK Genomic Revolution ETF filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other United States Health Care Equity funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.